Proliferation of breast cancer cells: regulation, mediators, targets for therapy.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Anti-Cancer Agents in Medicinal Chemistry

• Publication date

  2008-11-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/187152008786847747PMID 19075570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis

  2008cited by this paper
• Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

  2008cited by this paper
• Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.

  2008cited by this paper
• MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1.

  2008cited by this paper
• Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings

  2008cited by this paper
• Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes

  2008cited by this paper
• Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?

  2008cited by this paper
• A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

  2008cited by this paper
• Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.

  2007cited by this paper
• Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90

  2007cited by this paper
• Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor.

  2007cited by this paper
• Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.

  2007cited by this paper
• Inhibition of Estradiol Receptor/Src Association and Cell Growth by an Estradiol Receptor α Tyrosine-Phosphorylated Peptide

  2007cited by this paper
• The insulin-like growth factor 1 receptor in cancer: old focus, new future.

  2007cited by this paper
• Histone deacetylase inhibitors: signalling towards p21cip1/waf1.

  2007cited by this paper
• MAP kinase signalling pathways in cancer

  2007cited by this paper
• PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

  2007cited by this paper
• AKT/PKB signaling: navigating downstream.

  2007cited by this paper
• A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo

  2007cited by this paper
• Cancer stem cell: target for anti‐cancer therapy

  2007cited by this paper
• The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.

  2006cited by this paper
• Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.

  2006cited by this paper
• Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth

  2006cited by this paper
• Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.

  2006cited by this paper
• Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

  2006cited by this paper
• Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

  2006cited by this paper
• EGF–ERBB signalling: towards the systems level

  2006cited by this paper
• Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression

  2006cited by this paper
• Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

  2006cited by this paper
• The Consensus Coding Sequences of Human Breast and Colorectal Cancers

  2006cited by this paper
• Cell cycle control in breast cancer cells

  2006cited by this paper
• Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor–positive human breast cancer cells

  2006cited by this paper
• Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

  2006cited by this paper
• In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

  2006cited by this paper
• Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer.

  2006cited by this paper
• Current development of mTOR inhibitors as anticancer agents

  2006cited by this paper
• p21WAF1/CIP1 Selectively Controls the Transcriptional Activity of Estrogen Receptor α

  2005cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.

  2005cited by this paper
• Survival Signals Generated by Estrogen and Phospholipase D in MCF-7 Breast Cancer Cells Are Dependent on Myc

  2005cited by this paper
• Antiestrogen action of progesterone in breast tissue

  2005cited by this paper
• Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

  2005cited by this paper
• Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1.

  2005cited by this paper
• Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma In situ of the Breast

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Preclinical and Clinical Experience with Fulvestrant (Faslodex) in Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer

  2005cited by this paper
• PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors

  2005cited by this paper
• HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.

  2005cited by this paper
• mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes*

  2005cited by this paper
• Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

  2005cited by this paper
• Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.

  2004cited by this paper
• In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Arimidex®: A potent and selective fourth-generation aromatase inhibitor

  2004cited by this paper
• High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer

  2004cited by this paper
• Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase.

  2004cited by this paper
• Selective estrogen receptor modulation: concept and consequences in cancer.

  2004cited by this paper
• A methylation-mediator complex in hormone signaling.

  2004cited by this paper
• Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Self-renewal and solid tumor stem cells

  2004cited by this paper
• Breast Cancer Patients with Progesterone Receptor PR-A-Rich Tumors Have Poorer Disease-Free Survival Rates

  2004cited by this paper
• Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

  2003cited by this paper
• Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer

  2003cited by this paper
• Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.

  2003cited by this paper
• A role for cofactor–cofactor and cofactor–histone interactions in targeting p300, SWI/SNF and Mediator for transcription

  2003cited by this paper
• Estrogen receptor alpha and Sp1 regulate progesterone receptor gene expression.

  2003cited by this paper
• The genetics and genomics of cancer

  2003cited by this paper
• Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

  2003cited by this paper
• The deaf and the dumb: the biology of ErbB-2 and ErbB-3.

  2003cited by this paper
• Regulation of survivin function by Hsp90

  2003cited by this paper
• Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.

  2003cited by this paper
• Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.

  2003cited by this paper
• Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells.

  2003cited by this paper
• Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells.

  2003cited by this paper
• Estrogen receptor phosphorylation.

  2003cited by this paper
• Cellular actions of the insulin-like growth factor binding proteins.

  2002cited by this paper
• HDAC6 is a microtubule-associated deacetylase

  2002cited by this paper
• Loss of Co-ordinate Expression of Progesterone Receptors A and B is an Early Event in Breast Carcinogenesis

  2002cited by this paper
• Targeting of SWI/SNF chromatin remodelling complexes to estrogen‐responsive genes

  2002cited by this paper
• Cellular effects of purvalanol A: A specific inhibitor of cyclin‐dependent kinase activities

  2002cited by this paper
• Transcriptional activation by the oestrogen receptor α is modulated through inhibition of cyclin-dependent kinases

  2002cited by this paper
• Molecular Determinants for the Tissue Specificity of SERMs

  2002cited by this paper
• Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.

  2002cited by this paper
• Insulin/Insulin-like Growth Factor-I and Estrogen Cooperate to Stimulate Cyclin E-Cdk2 Activation and Cell Cycle Progression in MCF-7 Breast Cancer Cells through Differential Regulation of Cyclin E and p21WAF1/Cip1 *

  2001cited by this paper
• Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue

  2001cited by this paper
• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

  2001cited by this paper
• Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.

  2001cited by this paper
• Mechanisms of estrogen action.

  2001cited by this paper
• Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Coregulator Codes of Transcriptional Regulation by Nuclear Receptors*

  2001cited by this paper
• Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.

  2001cited by this paper
• Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.

  2000cited by this paper
• Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer

  2000cited by this paper
• 17β-Estradiol Inhibits Apoptosis in MCF-7 Cells, Inducing bcl-2 Expression via Two Estrogen-Responsive Elements Present in the Coding Sequence

  2000cited by this paper
• The Pezcoller lecture: cancer cell cycles revisited.

  2000cited by this paper
• Reciprocal Regulation via Protein-Protein Interaction between c-Myc and p21 cip1/waf1/sdi1 in DNA Replication and Transcription*

  2000cited by this paper

• Genetic analysis of PALB2 gene WD40 domain in canine mammary tumour patients

  2024cites this paper
• Identification of Hub of the Hub-Genes From Different Individual Studies for Early Diagnosis, Prognosis, and Therapies of Breast Cancer

  2024cites this paper
• The WHO claims estrogens are ‘carcinogenic’: is this true?

  2023cites this paper
• Surface roughness modulates EGFR signaling and stemness of triple-negative breast cancer cells

  2023cites this paper
• A Review on Computational Analysis of Big Data in Breast Cancer for Predicting Potential Biomarkers.

  2022cites this paper
• Tissue-Specific Upregulation of Drosophila Insulin Receptor (InR) Mitigates Poly(Q)-Mediated Neurotoxicity by Restoration of Cellular Transcription Machinery

  2018cites this paper
• Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation

  2018cites this paper
• PRKN (arkin RBR E3 ubiquitin protein ligase )

  2018cites this paper
• Knockdown of Chloride Channel-3 Inhibits Breast Cancer Growth In Vitro and In Vivo

  2018cites this paper
• Overexpression of caspase 7 is ERα dependent to affect proliferation and cell growth in breast cancer cells by targeting p21Cip

  2016cites this paper
• Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells.

  2015cites this paper
• O-naphthoquinone isolated from Capraria biflora L. induces selective cytotoxicity in tumor cell lines.

  2015cites this paper
• RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy

  2014cites this paper
• Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events

  2014cites this paper
• Citotoxic activity evaluation of essential oils and nanoemulsions of Drimys angustifolia and D. brasiliensis on human glioblastoma (U-138 MG) and human bladder carcinoma (T24) cell lines in vitro

  2013cites this paper
• Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer.

  2013cites this paper
• RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy

  2013cites this paper
• Identifying Grade/Stage-Related Active Modules in Human Co-regulatory Networks: A Case Study for Breast Cancer

  2012cites this paper
• Proteomics of invasiveness of human breast epithelial cells

  2012cites this paper
• Contribution of Xanthine Oxidoreductase to Mammary Epithelial and Breast Cancer Cell Differentiation In Part Modulates Inhibitor of Differentiation-1

  2011cites this paper
• The Role of Phosphoinositide Signaling in Breast Cancer Metastasis Suppressor 1-Mediated Metastasis Suppression of Human Breast Carcinoma Cells

  2011cites this paper
• Efeito antitumoral, genotóxico e mutagênico de nitensidina A em camundongos nude BALB/c com implante tumoral xenográfico de células imortalizadas com HPV-16 (SiHa)

  2011cites this paper
• PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer

  2011cites this paper
• Overexpression of fucosyltransferase IV promotes A431 cell proliferation through activating MAPK and PI3K/Akt signaling pathways

  2010cites this paper
• Risk of breast cancer during hormone replacement therapy: mechanisms

  2010cites this paper
• Differential Up-regulation of MAP Kinase Phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun Converge in the Control of the Growth Arrest Versus Proliferation Response of MCF-7 Breast Cancer Cells to Phorbol Ester*

  2010cites this paper
• Flaxseed cotyledon fraction reduces tumour growth and sensitises tamoxifen treatment of human breast cancer xenograft (MCF-7) in athymic mice

  2010cites this paper
• Epigenetic opportunities and challenges in cancer.

  2010cites this paper
• A reason why the ERBB2 gene is amplified and not mutated in breast cancer

  2009cites this paper
• Flaxseed and pure secoisolariciresinol diglucoside, but not flaxseed hull, reduce human breast tumor growth (MCF-7) in athymic mice.

  2009cites this paper